Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $11.17 Consensus Target Price from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.17.

Several analysts recently weighed in on CMPX shares. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $3.38 on Tuesday. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $4.08. The company has a market capitalization of $465.05 million, a price-to-earnings ratio of -9.13 and a beta of 1.17. The firm’s fifty day moving average price is $2.31 and its 200 day moving average price is $1.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. Enavate Sciences GP LLC purchased a new position in Compass Therapeutics during the fourth quarter valued at approximately $11,293,000. Tang Capital Management LLC grew its position in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC grew its position in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC grew its position in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Compass Therapeutics by 512.5% in the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock worth $395,000 after acquiring an additional 227,864 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.